Results 171 to 180 of about 692,160 (279)

Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase. [PDF]

open access: yesAntimicrob Agents Chemother, 2023
Bonnard D   +15 more
europepmc   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

open access: yesEpilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer   +7 more
wiley   +1 more source

Allosteric Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase Based on N,N'-Diphenylurea. [PDF]

open access: yesChemMedChem
Chayka A   +11 more
europepmc   +1 more source

Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors. [PDF]

open access: yesACS Med Chem Lett, 2023
Torrente E   +20 more
europepmc   +1 more source

Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population

open access: yesEpilepsia, EarlyView.
Long‐term efficacy and safety of adjunctive cenobamate in a multinational Asian population. Open‐label extension (OLE) efficacy population included all patients who had taken ≥1 dose of study drug and had any seizure data during the OLE maintenance phase.
Sang Kun Lee   +20 more
wiley   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

open access: yesEpilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang   +3 more
wiley   +1 more source

Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds? [PDF]

open access: yesJ Med Chem
Tao H   +6 more
europepmc   +1 more source

Allosteric inhibitors of the main protease of SARS-CoV-2. [PDF]

open access: yesAntiviral Res, 2022
Samrat SK   +13 more
europepmc   +1 more source

Cysteine Peptidases in Antitumor Immunity: Unraveling Antigen‐Presenting Cell Regulation and Therapeutic Potential

open access: yesiMetaMed, EarlyView.
This review systematically summarizes the central role of cysteine peptidases in modulating antigen‐presenting cell (APC) function and antitumor immune responses, highlighting their critical significance in overcoming tumor immune evasion. Current research has established that cysteine peptidase subtypes, including cathepsins B, S, L, and X, exert ...
Yimao Wu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy